Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
GDOC Quote, Financials, Valuation and Earnings
Last price:
$34.10
Seasonality move
:
-3.57%
Day range:
$34.06 - $34.06
52-week range:
$28.34 - $37.33
Dividend yield:
0.33%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
66
Avg. volume:
4.5K
1-year change:
1.62%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
TMED
Trimedyne
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
$34.06 | -- | -- | -- | $0.11 | 0.33% | -- |
|
BMED
iShares Health Innovation Active ETF
|
$30.45 | -- | -- | -- | $0.01 | 0% | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
$25.92 | -- | -- | -- | $0.11 | 0% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$29.70 | -- | -- | -- | $0.09 | 0.86% | -- |
|
TMED
Trimedyne
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | 0.358 | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | 0.614 | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | 0.486 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 0.429 | -- | -- |
|
TMED
Trimedyne
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
TMED
Trimedyne
|
-- | -- | -- | -- | -- | -- |
Goldman Sachs Future Health Care Equity ETF vs. Competitors
-
Which has Higher Returns GDOC or BMED?
iShares Health Innovation Active ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat iShares Health Innovation Active ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- BMEDiShares Health Innovation Active ETF-- -- -- -
What do Analysts Say About GDOC or BMED?
Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Health Innovation Active ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than iShares Health Innovation Active ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than iShares Health Innovation Active ETF.
Company Buy Ratings Hold Ratings Sell Ratings GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 BMEDiShares Health Innovation Active ETF0 0 0 -
Is GDOC or BMED More Risky?
Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Health Innovation Active ETF has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.827%.
-
Which is a Better Dividend Stock GDOC or BMED?
Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.33%. iShares Health Innovation Active ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. iShares Health Innovation Active ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDOC or BMED?
Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than iShares Health Innovation Active ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than iShares Health Innovation Active ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while iShares Health Innovation Active ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for iShares Health Innovation Active ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -- BMEDiShares Health Innovation Active ETF-- -- -- --
-
Which has Higher Returns GDOC or FMED?
Fidelity Disruptive Medicine ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Fidelity Disruptive Medicine ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- -
What do Analysts Say About GDOC or FMED?
Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity Disruptive Medicine ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Fidelity Disruptive Medicine ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Fidelity Disruptive Medicine ETF.
Company Buy Ratings Hold Ratings Sell Ratings GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 FMEDFidelity Disruptive Medicine ETF0 0 0 -
Is GDOC or FMED More Risky?
Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fidelity Disruptive Medicine ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GDOC or FMED?
Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.33%. Fidelity Disruptive Medicine ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.11 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Fidelity Disruptive Medicine ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDOC or FMED?
Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Fidelity Disruptive Medicine ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Fidelity Disruptive Medicine ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Fidelity Disruptive Medicine ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Fidelity Disruptive Medicine ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- --
-
Which has Higher Returns GDOC or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About GDOC or IBBQ?
Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is GDOC or IBBQ More Risky?
Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GDOC or IBBQ?
Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.33%. Invesco Nasdaq Biotechnology ETF offers a yield of 0.86% to investors and pays a quarterly dividend of $0.09 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDOC or IBBQ?
Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns GDOC or TMED?
Trimedyne has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Trimedyne's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- TMEDTrimedyne-- -- -- -
What do Analysts Say About GDOC or TMED?
Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Trimedyne has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Trimedyne, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Trimedyne.
Company Buy Ratings Hold Ratings Sell Ratings GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 TMEDTrimedyne0 0 0 -
Is GDOC or TMED More Risky?
Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Trimedyne has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GDOC or TMED?
Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.33%. Trimedyne offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Trimedyne pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDOC or TMED?
Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Trimedyne quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Trimedyne's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Trimedyne's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Trimedyne. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -- TMEDTrimedyne-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 6.21% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 9.07% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 7.16% over the past day.
